{"id":526495,"date":"2021-08-11T07:24:55","date_gmt":"2021-08-11T11:24:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/"},"modified":"2021-08-11T07:24:55","modified_gmt":"2021-08-11T11:24:55","slug":"genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/","title":{"rendered":"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BEIJING, Aug.  11, 2021  (GLOBE NEWSWIRE) &#8212; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Beijing clinical laboratory has received full marks under the National Center for Clinical Laboratories\u2019 (\u201cNCCL\u201d) first nationwide, external quality assessment (\u201cEQA\u201d) of NGS-based comprehensive genomic profiling for solid tumors. The clinical laboratory passed the assessment with flying colors, earning the designation \u201cOutstanding Laboratory\u201d and receiving full marks, ranking first among all of the 63 laboratories that participated in the evaluation.<\/p>\n<p>High-throughput next generation sequencing (\u201cNGS\u201d) technology has been widely used in precision medicine. NGS-based comprehensive genomic profiling tests are able to cover more genes and mutations, and can direct patients towards more accurate treatment solutions. As such, comprehensive genomic profiling tests are increasingly becoming a trend in the clinical applications of precision oncology.<\/p>\n<p>In order to improve clinical laboratories\u2019 NGS-based comprehensive genomic profiling capabilities in China, the NCCL carried out a nationwide assessment for the first time. The assessment aims to point out various and common issues experienced by laboratories in the industry, and to improve the quality of industry practices.<\/p>\n<p>A total of 63 laboratories from 12 different provinces and municipalities in China participated in the EQA. Among the 63 valid results, 25.4% (16\/63) had no reproducibility errors, 12.7% (8\/63) had no false negative results, and 61.9% (39\/63) had no false positive results. Genetron Health participated in the assessment using its proprietary NGS-based comprehensive genomic profiling product, Onco PanScan<sup>\u2122<\/sup> and achieved full marks without any errors.<\/p>\n<p>Genetron Health\u2019s laboratories strictly adhere to a full-cycle quality control system. The Company has passed NCCL\u2019s EQAs with full marks for six consecutive years, attesting to its accurate detection capabilities and high quality operational standards. At present, Genetron Health\u2019s laboratory in Beijing has obtained three international laboratory quality certifications: CAP, CLIA and ISO15189, becoming one of the few NGS laboratories in China to possess them.<\/p>\n<p>\n        <strong>About Onco PanScan\u2122<\/strong><br \/>\n        <br \/>Onco PanScan\u2122\u00a0is Genetron\u2019s comprehensive genomic profiling test that is based on hybridization capture NGS technology. Onco PanScan\u2122\u00a0provides comprehensive and accurate genomic profiling to guide personalized medicine for cancer patients with a single test, making it suitable for targeted therapy, chemotherapy, and immunotherapy treatment guidance. Onco PanScan\u2122\u00a0covers hundreds of genes recommended by professional treatment guidelines, including WHO, NCCN, ESMO and others. In January 2020, the National Medical Products Administration (\u201cNMPA\u201d) initiated device inspection process for Onco PanScan\u2122, which is part of the IVD registration process in China.<\/p>\n<p>\n        <strong>About Genetron Holdings Limited<\/strong><br \/>\n        <br \/>Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.<\/p>\n<p>\n        <strong>Safe Harbor Statement<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of federal securities laws which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are made under the \u201csafe harbor\u201d provisions of the\u00a0U.S.\u00a0Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company\u2019s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as \u201cmay\u201d, \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cis\/are likely to\u201d or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company\u2019s filings with the\u00a0SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.<\/p>\n<p>Investor Relations Contact<br \/>US:<br \/>Hoki Luk<br \/>Email: hoki.luk@genetronhealth.com<br \/>Phone: +1 (408) 891-9255<\/p>\n<p>Media Relations Contact<br \/>Yanrong Zhao<br \/>yanrong.zhao@genetronhealth.com<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NjZhNmZjZDItYTZjNy00ZTlkLWExN2EtYzEyNzlhMzNhZjY5LTEyMDE3MTY=\/tiny\/Genetron-Holdings-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEIJING, Aug. 11, 2021 (GLOBE NEWSWIRE) &#8212; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Beijing clinical laboratory has received full marks under the National Center for Clinical Laboratories\u2019 (\u201cNCCL\u201d) first nationwide, external quality assessment (\u201cEQA\u201d) of NGS-based comprehensive genomic profiling for solid tumors. The clinical laboratory passed the assessment with flying colors, earning the designation \u201cOutstanding Laboratory\u201d and receiving full marks, ranking first among all of the 63 laboratories that participated in the evaluation. High-throughput next generation sequencing (\u201cNGS\u201d) technology has been widely used in precision medicine. NGS-based comprehensive genomic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-526495","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEIJING, Aug. 11, 2021 (GLOBE NEWSWIRE) &#8212; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Beijing clinical laboratory has received full marks under the National Center for Clinical Laboratories\u2019 (\u201cNCCL\u201d) first nationwide, external quality assessment (\u201cEQA\u201d) of NGS-based comprehensive genomic profiling for solid tumors. The clinical laboratory passed the assessment with flying colors, earning the designation \u201cOutstanding Laboratory\u201d and receiving full marks, ranking first among all of the 63 laboratories that participated in the evaluation. High-throughput next generation sequencing (\u201cNGS\u201d) technology has been widely used in precision medicine. NGS-based comprehensive genomic &hellip; Continue reading &quot;Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-11T11:24:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks\",\"datePublished\":\"2021-08-11T11:24:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/\"},\"wordCount\":747,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/\",\"name\":\"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=\",\"datePublished\":\"2021-08-11T11:24:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/","og_locale":"en_US","og_type":"article","og_title":"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks - Market Newsdesk","og_description":"BEIJING, Aug. 11, 2021 (GLOBE NEWSWIRE) &#8212; Genetron Holdings Limited (\u201cGenetron Health\u201d or the \u201cCompany\u201d, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Beijing clinical laboratory has received full marks under the National Center for Clinical Laboratories\u2019 (\u201cNCCL\u201d) first nationwide, external quality assessment (\u201cEQA\u201d) of NGS-based comprehensive genomic profiling for solid tumors. The clinical laboratory passed the assessment with flying colors, earning the designation \u201cOutstanding Laboratory\u201d and receiving full marks, ranking first among all of the 63 laboratories that participated in the evaluation. High-throughput next generation sequencing (\u201cNGS\u201d) technology has been widely used in precision medicine. NGS-based comprehensive genomic &hellip; Continue reading \"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-11T11:24:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks","datePublished":"2021-08-11T11:24:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/"},"wordCount":747,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/","name":"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=","datePublished":"2021-08-11T11:24:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzEyMyM0MzUzMDU2IzIxOTAxNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genetron-health-tops-nccls-external-quality-assessment-of-ngs-based-comprehensive-genomic-profiling-for-solid-tumors-with-full-marks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genetron Health Tops NCCL\u2019s External Quality Assessment of NGS-based Comprehensive Genomic Profiling for Solid Tumors with Full Marks"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=526495"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526495\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=526495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=526495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=526495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}